BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, December 4, 2025
See today's BioWorld MedTech
Home
» Saluda to expand spinal cord stimulation market in AU$231M IPO
To read the full story,
subscribe
or
sign in
.
Saluda to expand spinal cord stimulation market in AU$231M IPO
Dec. 4, 2025
By
Tamra Sami
Saluda Medical Pty Ltd. announced a AU$231 million ($152.7 million) initial public offering on the Australian Securities Exchange to scale up its U.S. footprint for its Evoke spinal cord simulation system for chronic pain.
BioWorld MedTech
Financings
Neurology/psychiatric
IPO
Medical devices
Asia-Pacific